Abstract: A method of treating a disorder in a subject. The method comprises administering to said subject an effective amount of an agonist of the melanocortin-4 receptor (MC4R). The subject is a heterozygous carrier of an MC4R mutation, and the disorder results from an attenuated response of MC4R to ?-melanocortin stimulating hormone (?-MSH).
Type:
Grant
Filed:
November 13, 2020
Date of Patent:
July 18, 2023
Assignee:
RHYTHM PHARMACEUTICALS, INC.
Inventors:
Louis Anthony Tartaglia, Bart Henderson, Leonardus H. T. Van Der Ploeg
Abstract: The present invention relates to an ionic complex comprising a cationic polypeptide and an anionic excipient selected from: a PEG-carboxylic acid; a fatty acid having 10 or more carbon atoms; an anionic phospholipid; and a combination thereof. The invention also relates to a pharmaceutical composition comprising the ionic complex of the invention and a pharmaceutically acceptable carrier. The cationic polypeptide of the ionic complex has pharmacological activity and the complex can provide a more desirable pharmacokinetic profile for the cationic polypeptide of the complex as compared to the cationic polypeptide alone following administration. As such, the invention also relates to the use of the ionic complex and pharmaceutical composition comprising same to treat a subject suffering from a disease or disorder that is responsive to the cationic polypeptide of the ionic complex.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
September 28, 2021
Assignee:
RHYTHM PHARMACEUTICALS, INC.
Inventors:
Shubh Sharma, Leonardus H. T. Van Der Ploeg, Bart Henderson
Abstract: The disclosure is related to a method of treating a disorder, such as Prader Willi Syndrome (PWS), obesity or hyperphagia, in a subject using a melanocortin-4 receptor (MC4R) agonist. Also described is method of treating a subject having a deficiency in the pro-opiomelanocortin (POMC)-MC4R pathway, such as a POMC-null or a PCSK-null subject, using a MC4R agonist.
Type:
Grant
Filed:
September 29, 2016
Date of Patent:
March 30, 2021
Assignees:
RHYTHM PHARMACEUTICALS, INC., CHARITÉ—UNIVERSITÄTSMEDIZIN BERLIN
Inventors:
Leonardus H. T. Van Der Ploeg, Bart Henderson, Peter Kuhnen
Abstract: A method of treating a disorder in a subject. The method comprises administering to said subject an effective amount of an agonist of the melanocortin-4 receptor (MC4R). The subject is a heterozygous carrier of an MC4R mutation, and the disorder results from an attenuated response of MC4R to ?-melanocortin stimulating hormone (?-MSH).
Type:
Grant
Filed:
April 15, 2019
Date of Patent:
March 23, 2021
Assignee:
RHYTHM PHARMACEUTICALS, INC.
Inventors:
Louis Anthony Tartaglia, Bart Henderson, Leonardus H. T. Van Der Ploeg
Abstract: The present invention relates to polypeptide compounds that are modulators (e.g., agonists and antagonists) of the melanocortin-4 receptor (MC4R) and pharmaceutical compositions comprising same. The compounds described herein are polypeptide of the following structural Formula (I): or a pharmaceutically acceptable salt thereof. Values and preferred values of the variables in structural Formula (I) are described herein.
Type:
Grant
Filed:
December 11, 2018
Date of Patent:
December 8, 2020
Assignee:
RHYTHM PHARMACEUTICALS, INC.
Inventors:
Shubh Sharma, Leonardus H. T. Van Der Ploeg, Bart Henderson
Abstract: The present invention relates to polypeptide compounds that are modulators (e.g., agonists and antagonists) of the melanocortin-4 receptor (MC4R) and pharmaceutical compositions comprising same. The compounds described herein are polypeptide of the following structural Formula (I): or a pharmaceutically acceptable salt thereof. Values and preferred values of the variables in structural Formula (I) are described herein.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
February 5, 2019
Assignee:
RHYTHM PHARMACEUTICALS, INC.
Inventors:
Shubh Sharma, Leonardus H. T. Van Der Ploeg, Bart Henderson
Abstract: A method of treating a disorder in a subject. The method comprises administering to said subject an effective amount of an agonist of the melanocortin-4 receptor (MC4R). The subject is a heterozygous carrier of an MC4R mutation, and the disorder results from an attenuated response of MC4R to ?-melanocortin stimulating hormone (?-MSH).
Type:
Grant
Filed:
October 20, 2017
Date of Patent:
January 1, 2019
Assignee:
RHYTHM PHARMACEUTICALS, INC.
Inventors:
Louis Anthony Tartaglia, Bart Henderson
Abstract: The disclosure is related to a method of treating a disorder, such as obesity or a condition associated with obesity, such as hyperphagia, in a subject using a melanocortin-4 receptor (MC4R) agonist.
Type:
Application
Filed:
September 29, 2016
Publication date:
August 2, 2018
Applicant:
Rhythm Pharmaceuticals, Inc.
Inventors:
Leonardus H.T. Van Der Ploeg, Bart Henderson, Shubh Sharma
Abstract: A method of treating a disorder in a subject. The method comprises administering to said subject an effective amount of an agonist of the melanocortin-4 receptor (MC4R). The subject is a heterozygous carrier of an MC4R mutation, and the disorder results from an attenuated response of MC4R to a-melanocortin stimulating hormone (a-MSH).